Severe oral erosive lichenoid reaction to pembrolizumab therapy

Indraneel Bhattacharyya, Hardeep Chehal, Cesar Migliorati

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


New advances in cancer immunotherapy have been flooding the market at a rapid rate. Pembrolizumab (Keytruda), a programmed cell death protein 1 inhibitor, introduced in 2014, has been used to treat several cancers. Immune-related adverse events associated with pembrolizumab and other immune checkpoint inhibitors are now well-described complications. We describe the case of a 65-year old female with severe oral lichenoid lesions occurring after treatment with pembrolizumab for bladder cancer. To the best of our knowledge, this is the first report of a biopsy-proven oral erosive lichenoid reaction confirmed through direct immunofluorescence.

Original languageEnglish (US)
Pages (from-to)e301-e307
JournalOral surgery, oral medicine, oral pathology and oral radiology
Issue number5
StatePublished - Nov 2020

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oral Surgery
  • Pathology and Forensic Medicine
  • Dentistry (miscellaneous)
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Severe oral erosive lichenoid reaction to pembrolizumab therapy'. Together they form a unique fingerprint.

Cite this